Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03824938 (ClinicalTrials.gov)	April 30, 2019	9/1/2019	Aspirin for Exercise in Multiple Sclerosis (ASPIRE)	Aspirin for Exercise in Multiple Sclerosis (ASPIRE): A Double-Blind RCT of Aspirin or Acetaminophen Pretreatment to Improve Exercise Performance in Multiple Sclerosis (MS)	Multiple Sclerosis	Drug: Aspirin 650mg Oral Capsule;Drug: Acetaminophen Tab 650mg;Other: Placebo	Columbia University	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	18 Years	70 Years	All	60	Phase 1/Phase 2	United States
2	NCT03051646 (ClinicalTrials.gov)	January 13, 2017	8/2/2017	Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis	A Placebo-controlled Double Blind Crossover Trial of Acetylsalicylic Acid as a Pre-treatment for Exercise in Multiple Sclerosis	Fatigue;Overheating	Drug: Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit;Drug: Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit	Columbia University	National Multiple Sclerosis Society	Completed	18 Years	60 Years	All	12	Early Phase 1	United States
3	EUCTR2013-001895-40-IE (EUCTR)	02/05/2014	06/03/2014	A study to evaluate the effect of aspirin on flushing in patients with RRMS treated with Tecfidera	A Phase 4, Randomized, Double-Blind Study with a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects with Relapsing-Remitting Multiple Sclerosis Treated with Tecfidera™ (dimethyl fumarate) delayed-release capsules (ASSURE) - ASSURE	Relapsing-Remitting Multiple Sclerosis MedDRA version: 16.1;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 16.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tecfidera Product Name: Tecfidera Product Code: BG00012 INN or Proposed INN: DIMETHYL FUMARATE Other descriptive name: DIMETHYL FUMARATE Trade Name: Tecfidera Product Name: Tecfidera Product Code: BG00012 INN or Proposed INN: DIMETHYL FUMARATE Other descriptive name: DIMETHYL FUMARATE Trade Name: Micropirin INN or Proposed INN: ACETYLSALICYLIC ACID Other descriptive name: ASA	Biogen Idec Research Limited	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 4	Ireland;United Kingdom
4	NCT02090413 (ClinicalTrials.gov)	May 2014	14/3/2014	Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis	A Phase 4, Randomized, Double-Blind Study With a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects With Relapsing-Remitting Multiple Sclerosis Treated With Tecfidera® (Dimethyl Fumarate) Delayed-Release Capsules	Relapsing-Remitting Multiple Sclerosis	Drug: dimethyl fumarate;Drug: acetylsalicylic acid;Drug: ASA-Placebo	Biogen	NULL	Completed	18 Years	N/A	All	241	Phase 4	Ireland;United Kingdom
5	NCT00467584 (ClinicalTrials.gov)	July 2007	26/4/2007	Aspirin for Treatment of Multiple Sclerosis-Related Fatigue	Aspirin for Treatment of Multiple Sclerosis-Related Fatigue	Multiple Sclerosis;Fatigue	Drug: High Dose Aspirin (1300 mg/day);Drug: Low Dose Aspirin (162 mg/day);Drug: Placebo	Mayo Clinic	National Multiple Sclerosis Society	Terminated	18 Years	65 Years	All	62	Phase 3	United States

先頭へ